Calidi Biotherapeutics, Inc. (CLDI) stock
CLDINYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CLDWW
$0.56−0.04 (-7.07%)
Close on Nov 17, 2026Market cap $1.45MP/E –Yield –
Calidi Biotherapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Calidi Biotherapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$17.75M. For fiscal 2025 it was -$21.29M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$21.29M | – |
| FY2024 | Dec 31, 2024 | -$19.69M | – |
| FY2023 | Dec 31, 2023 | -$26.98M | – |
| FY2022 | Dec 31, 2022 | -$13.21M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.35M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.12M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.04M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.24M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.88M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.13M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.42M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.95M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.49M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.19M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.52M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.17M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.11M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.88M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.60M | – |
| Q2 FY2022 | Jun 30, 2022 | -$268.68K | – |
| Q1 FY2022 | Mar 31, 2022 | -$465.13K | – |
| Q2 FY2021 | Jun 30, 2021 | -$118.80K | – |
See a number that looks wrong?